1lyx › Citations

Structure of the Plasmodium falciparum triosephosphate isomerase-phosphoglycolate complex in two crystal forms: characterization of catalytic loop open and closed conformations in the ligand-bound state.

Parthasarathy S, Ravindra G, Balaram H, Balaram P, Murthy MR
Biochemistry 41 13178-88 (2002)
Cited: 24 times
EuropePMC logo PMID: 12403619

Abstract

Triosephosphate isomerase (TIM) has been the subject of many structural and mechanistic studies. At position 96, there is a highly conserved Ser residue, which is proximal to the catalytic site. Thus far, no specific role has been ascribed to this residue. Plasmodium falciparum TIM (PfTIM), a fully catalytically active enzyme, is unique in possessing a Phe residue at position 96. The structure of PfTIM complexed to phosphoglycolate (PG), a transition state analogue, has been determined in an effort to probe the effects of the mutation at residue 96 on the nature of inhibitor-enzyme interactions and the orientation of the critical catalytic loop (loop 6, residues 166-176) in TIM. Crystal structures of PfTIM complexed to phosphoglycolate in orthorhombic (P2(1)2(1)2(1)) and monoclinic (C2) forms were determined and refined at resolutions of 2.8 and 1.9 A, respectively. The P2(1)2(1)2(1) form contains two dimers in the asymmetric unit. In the C2 form, the molecular and crystal 2-fold axes are coincident, leading to a monomer in the asymmetric unit. The catalytic loop adopts the open state in the P2(1)2(1)2(1) form and the closed conformation in the C2 crystal. The open conformation of the loop in the P2(1)2(1)2(1) form appears to be a consequence of the Ser to Phe mutation at residue 96. The steric clash between Phe96 and Ile172 probably impedes loop closure in PfTIM-ligand complexes. The PfTIM-PG complex is the first example of a TIM-ligand complex being observed in both loop open and closed forms. In the C2 form (loop closed), Phe96 and Leu167 adopt alternative conformations that are different from the ones observed in the open form, permitting loop closure. These structures provide strong support for the view that loop closure is not essential for ligand binding and that dynamic loop movement may occur in both free and ligand-bound forms of the enzyme.

Reviews - 1lyx mentioned but not cited (2)

  1. Heterologous expression of plasmodial proteins for structural studies and functional annotation. Birkholtz LM, Blatch G, Coetzer TL, Hoppe HC, Human E, Morris EJ, Ngcete Z, Oldfield L, Roth R, Shonhai A, Stephens L, Louw AI. Malar J 7 197 (2008)
  2. The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations. Ogungbe IV, Setzer WN. Molecules 21 E1389 (2016)

Articles - 1lyx mentioned but not cited (7)

  1. The critical role of the loops of triosephosphate isomerase for its oligomerization, dynamics, and functionality. Katebi AR, Jernigan RL. Protein Sci 23 213-228 (2014)
  2. The evolutionary origins and catalytic importance of conserved electrostatic networks within TIM-barrel proteins. Livesay DR, La D. Protein Sci 14 1158-1170 (2005)
  3. Featured Species-Specific Loops Are Found in the Crystal Structure of Mhp Eno, a Cell Surface Adhesin From Mycoplasma hyopneumoniae. Chen R, Yu Y, Feng Z, Gan R, Xie X, Zhang Z, Xie Q, Wang W, Ran T, Zhang W, Xiong Q, Shao G. Front Cell Infect Microbiol 9 209 (2019)
  4. Brazilian malaria molecular targets (BraMMT): selected receptors for virtual high-throughput screening experiments. Nunes RR, Fonseca ALD, Pinto ACS, Maia EHB, Silva AMD, Varotti FP, Taranto AG. Mem Inst Oswaldo Cruz 114 e180465 (2019)
  5. Allosteric transition and binding of small molecule effectors causes curvature change in central β-sheets of selected enzymes. Tolonen E, Bueno B, Kulshreshta S, Cieplak P, Argáez M, Velázquez L, Stec B. J Mol Model 17 899-911 (2011)
  6. Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs. Banfi FF, Krombauer GC, da Fonseca AL, Nunes RR, Andrade SN, de Rezende MA, Chaves MH, Monção EDS, Taranto AG, Rodrigues DJ, Vieira GM, de Castro WV, Varotti FP, Sanchez BAM. J Venom Anim Toxins Incl Trop Dis 27 e20200073 (2021)
  7. In vitro and in silico assessment of new beta amino ketones with antiplasmodial activity. Krombauer GC, Guedes KS, Banfi FF, Nunes RR, Fonseca ALD, Siqueira EP, Bellei JCB, Scopel KKG, Varotti FP, Sanchez BAM. Rev Soc Bras Med Trop 55 e0590 (2022)


Reviews citing this publication (2)

  1. Triosephosphate isomerase: a highly evolved biocatalyst. Wierenga RK, Kapetaniou EG, Venkatesan R. Cell Mol Life Sci 67 3961-3982 (2010)
  2. A guide to the effects of a large portion of the residues of triosephosphate isomerase on catalysis, stability, druggability, and human disease. Olivares-Illana V, Riveros-Rosas H, Cabrera N, Tuena de Gómez-Puyou M, Pérez-Montfort R, Costas M, Gómez-Puyou A. Proteins 85 1190-1211 (2017)

Articles citing this publication (13)

  1. Plasmodium falciparum enolase: stage-specific expression and sub-cellular localization. Bhowmick IP, Kumar N, Sharma S, Coppens I, Jarori GK. Malar J 8 179 (2009)
  2. Closed conformation of the active site loop of rabbit muscle triosephosphate isomerase in the absence of substrate: evidence of conformational heterogeneity. Aparicio R, Ferreira ST, Polikarpov I. J Mol Biol 334 1023-1041 (2003)
  3. Structure of N-acetyl-beta-D-glucosaminidase (GcnA) from the endocarditis pathogen Streptococcus gordonii and its complex with the mechanism-based inhibitor NAG-thiazoline. Langley DB, Harty DW, Jacques NA, Hunter N, Guss JM, Collyer CA. J Mol Biol 377 104-116 (2008)
  4. How an Inhibitor Bound to Subunit Interface Alters Triosephosphate Isomerase Dynamics. Kurkcuoglu Z, Findik D, Akten ED, Doruker P. Biophys J 109 1169-1178 (2015)
  5. Structural effects of a dimer interface mutation on catalytic activity of triosephosphate isomerase. The role of conserved residues and complementary mutations. Banerjee M, Balaram H, Balaram P. FEBS J 276 4169-4183 (2009)
  6. Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers? Kim KH. J Comput Aided Mol Des 21 421-435 (2007)
  7. Triosephosphate isomerase: 15N and 13C chemical shift assignments and conformational change upon ligand binding by magic-angle spinning solid-state NMR spectroscopy. Xu Y, Lorieau J, McDermott AE. J Mol Biol 397 233-248 (2010)
  8. Kinetic and structural properties of triosephosphate isomerase from Helicobacter pylori. Chu CH, Lai YJ, Huang H, Sun YJ. Proteins 71 396-406 (2008)
  9. Crystal structures of triosephosphate isomerase from methicillin resistant Staphylococcus aureus MRSA252 provide structural insights into novel modes of ligand binding and unique conformations of catalytic loop. Mukherjee S, Roychowdhury A, Dutta D, Das AK. Biochimie 94 2532-2544 (2012)
  10. Structures of unliganded and inhibitor complexes of W168F, a Loop6 hinge mutant of Plasmodium falciparum triosephosphate isomerase: observation of an intermediate position of loop6. Eaazhisai K, Balaram H, Balaram P, Murthy MR. J Mol Biol 343 671-684 (2004)
  11. Coupling of structural fluctuations to deamidation reaction in triosephosphate isomerase by Gaussian network model. Konuklar FA, Aviyente V, Haliloğlu T. Proteins 62 715-727 (2006)
  12. Detection of the protein dimers, multiple monomeric states and hydrated forms of Plasmodium falciparum triosephosphate isomerase in the gas phase. Thakur SS, Deepalakshmi PD, Gayathri P, Banerjee M, Murthy MR, Balaram P. Protein Eng Des Sel 22 289-304 (2009)
  13. Structural assessment of glycyl mutations in invariantly conserved motifs. Prakash T, Sandhu KS, Singh NK, Bhasin Y, Ramakrishnan C, Brahmachari SK. Proteins 69 617-632 (2007)


Related citations provided by authors (1)

  1. Triosephosphate isomerase from Plasmodium falciparum: Crystal structure provides insights into antimalarial drug design. Velankar SS, Ray SS, Gokhle RS, Suma S, Balaram H, Balaram P, Murthy MRN Structure 5 751-761 (1997)

Quick links